We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.25
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.50 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 20.25
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options

14 Jun 2018 07:00

RNS Number : 3777R
Iofina PLC
14 June 2018
 

 

14 June 2018

Iofina plc

("Iofina" or the "Company")

Grant of Share Options

 

Iofina (AIM: IOF), specialists in the exploration and production of iodine and iodine specialty chemical derivatives, announces that it has, effective from 13 June 2018, adopted an updated share option plan for the incentivisation and retention of key personnel. The Company adopted its initial share option plan in 2008 (the "2008 Plan"), the terms of which have not been previously amended or otherwise updated. The Company's board of directors (the "Board") considered it to be the appropriate time to review the terms of the 2008 Plan to assess whether any changes should be made to the terms to reflect the Company's current strategy and update any obsolete federal and/or regulatory references. The Board resolved to update the 2008 Plan to ensure it remains fit for purpose. The updated share option plan of the Company is to be known as the "Iofina plc 2018 Stock Option Plan" (the "2018 Plan").

The Company further announces that it granted on 13 June 2018, in aggregate, 1,980,000 share awards in the form of options over ordinary shares in the capital of the Company ("Ordinary Shares") under the 2018 Plan (the "2018 Options"). As at today's date, the options represent approximately 1.55 per cent. of the current issued share capital of the Company.

The 2018 Options will be exercisable at a price of 16.2 pence per Ordinary Share (being the closing price on 12 June 2018), with 50 per cent. vesting one year from the date of grant and the remaining 50 per cent. vesting two years from the date of grant. The 2018 Options are exercisable at any time prior to (and including) the day falling on the tenth anniversary of grant. In the event that any option holder leaves the Company, they will have a period of 90 days within which to exercise any vested options failing which they will lapse (the "90 Days Condition").

The grant of options under the 2018 Plan is part of the Company's long-term incentive arrangements designed to align the interests of the shareholders and certain executives.

There remain outstanding 985,000 share awards in the form of options over Ordinary Shares granted on 2 July 2011 under the 2008 Plan (the "2008 Options"), representing approximately 0.77 per cent. of the current issued share capital of the Company. The 2008 Options are exercisable at 30 pence per Ordinary Share and are exercisable up to (and including) 2 July 2021. The 90 Days Condition is also applicable to the 2008 Options.

The 2018 Options and the 2008 Options represent, in aggregate, approximately 2.33 per cent. of the current issued share capital of the Company.

In accordance with the requirements of the EU Market Abuse Regulation the 2018 Options have been granted to PDMRs under the 2018 Plan.

The total options granted over Ordinary Shares under the 2008 Plan and the 2018 Plan are detailed below.

Name

2008 Options granted

Exercise price per 2008 Option

Lapse date

2018 Options granted

Exercise price per 2018 Option

Lapse date

Thomas Becker

250,000

30 pence

02/07/21

660,000

16.2 pence

13/06/28

Malcolm Lewin

-

-

-

330,000

16.2 pence

13/06/28

Lance Baller

-

-

-

220,000

16.2 pence

13/06/28

William Bellamy

-

-

-

110,000

16.2 pence

13/06/28

Forest Dorn

350,000

30 pence

02/07/21

220,000

16.2 pence

13/06/28

Kurt Jones

125,000

30 pence

02/07/21

220,000

16.2 pence

13/06/28

Scott Formolo

100,000

30 pence

02/07/21

220,000

16.2 pence

13/06/28

Michael Coddington

100,000

30 pence

02/07/21

-

-

-

Other employees (non-PDMRs)

60,000

30 pence

02/07/21

-

-

-

 

 

Enquiries:

 

Iofina plc

Dr. Tom Becker, CEO & President

Tel: +44 (0)20 3006 3135

 

finnCap Ltd

Christopher Raggett/Giles Rolls/Camille Gochez

Tel: +44 (0)20 7220 0500

 

Media Contact:

Yellow Jersey

Charles Goodwin/Harriet Jackson

Tel: +44 (0)7544 275 882

 About Iofina:

Iofina specialises in the exploration and production of iodine, halogen based specialty chemical derivatives and produced water. Iofina's business strategy is to identify, develop, build, own and operate iodine extraction plants currently focused in North America, based on Iofina's WET® IOsorb® technology. Iofina has production operations in the United States, specifically in Kentucky and Oklahoma. It is a vertically integrated company, covering the process from the production of iodine in the field, to the manufacture of the chemical end-products derived from iodine, supplying them to the consumer, and the recycling of iodine using iodinated side-streams from waste chemical processes. Iofina utilises its portfolio of patented and patent-pending technology, and proprietary methods and trademarks throughout all business lines.

www.iofina.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGUGDLRXBBGIS
Date   Source Headline
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.